Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.

BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA

The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE: BDX) BD Veritor At-Home COVID-19 Test. Also Read:   BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV

BD Locks FDA Emergency Use Nod For At-Home COVID-19 Antigen Test

FRANKLIN LAKES, N.J., Aug. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BD Veritor™ At-Home COVID-19 Test — the first at-home COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide a digital display of testing results.

BD Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results

Becton Dickinson and Co (NYSE: BDX) has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus (HPV). The modular and scalable BD Cor includes an automated sample preparation system, BD Cor PX, and an instrument that automates the BD Onclarity HPV assay, BD Cor GX.

BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV

FRANKLIN LAKES, N.J., Aug. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has launched a new, fully automated high-throughput diagnostic system using robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the United States.

BD Launches Fully Automated High-Throughput Molecular Diagnostic Platform for U.S. Laboratories

FRANKLIN LAKES, N.J., Aug. 19, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash (i) any and all of the Company's 2.894% senior notes due 2022 and 3.300% senior notes due 2023, each listed in the first table below (the "Any and All Notes"), and (ii) in the order of priority set forth in the second table below, up to the applicable Maximum Tender SubCap, if any, of each of the Company's 3.875% senior notes due 2024, 3.734% senior notes due 2024 and 3.363% senior notes due 2024, each listed in the second table below (collectively, the "Maximum Tender Offer Notes" and together with the Any and All Notes, the "Securities" and each a "series"), subject to an aggregate maximum tender cap of $1,285,000,000 for all tendered series of Maximum Tender Offer Notes (the "Aggregate Maximum Tender Cap").

BD Announces Pricing of Tender Offers

FRANKLIN LAKES, N.J., Aug. 19, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash (i) any and all of the Company's 2.894% senior notes due 2022 and 3.300% senior notes due 2023, each listed in the first table below (the "Any and All Notes"), and (ii) in the order of priority set forth in the second table below, up to the applicable Maximum Tender SubCap of each of the Company's 3.875% senior notes due 2024, 3.734% senior notes due 2024 and 3.363% senior notes due 2024, each listed in the second table below (collectively, the "Maximum Tender Offer Notes" and together with the Any and All Notes, the "Securities" and each a "series"), subject to an aggregate maximum tender cap of $1,285,000,000 (the "Aggregate Maximum Tender Cap").

Becton, Dickinson and Company Announces Early Tender Results

BD's (BDX) latest product offering is expected to help improve access to instrumentation for complex scientific research to more laboratories.

BD's (BDX) New Offering to Boost Labs' Flow Cytometry Abilities

FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes.

New BD Benchtop Cell Analyzer Enhances Laboratory Access and Accelerates Scientific Research

FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher DelOrefice has been named executive vice president and chief financial officer (CFO), effective Sept.

Christopher DelOrefice to Join BD as Chief Financial Officer

FRANKLIN LAKES, N.J., Aug. 10, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has amended its previously announced tender offers to purchase for cash each of its 3.875% Senior Notes due 2024, 3.734% Senior Notes due 2024 and 3.363% Senior Notes due 2024 (collectively, the "Maximum Tender Offer Notes") to (i) increase the previously announced maximum principal amount to be purchased by the Company of its 3.734% Senior Notes due 2024 from $300,000,000 to $500,000,000 and (ii) increase the previously announced maximum principal amount to be purchased by the Company of all series of Maximum Tender Offer Notes in the tender offers from $715,000,000 to $1,285,000,000.

BD Announces Upsizing of Tender Offers

JPMorgan downgraded Becton Dickinson and Co (NYSE:BDX) to Neutral from Overweight with a price target of $265, down from $280.  While Becton reported better than expected top and bottom-line Q3 results, analyst Robert Marcus tells investors that this was overshadowed by the company's "muted" Q4 and FY22 outlook.

JPMorgan Downgrades Becton Dickinson On Muffled FY22 Outlook

Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript

Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal third quarter, thus driving up the overall top line.

BD (BDX) Beats on Q3 Earnings and Revenues, Ups '21 View

FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the tables below (collectively, the "Securities" and each a "series").

Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.38% and 8.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates

Becton Dickinson and Co (NYSE: BDX) reported Q3 revenues of $4.9 billion, +26.9% Y/Y, better than the consensus of $4.51 billion. The increase is primarily driven by the strong base business performance as overall healthcare utilization levels recover from the initial impact of COVID-19.

BDX Stock Plunges Despite Q3 Earnings Topping Estimates On Recovery In Elective Volumes; Raised FY21 Guidance

Shares of Becton, Dickinson (NYSE:BDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 24.55% year over year to $2.74, which beat the estimate of $2.44.

Becton, Dickinson: Q3 Earnings Insights

FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ -- Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis.

BD Announces Third Fiscal Quarter Results; Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021

FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher Reidy, 64, executive vice president, chief financial officer (CFO) and chief administrative officer (CAO), has informed the company of his intent to retire as he reaches retirement eligibility.

Christopher Reidy Announces Intent to Retire from BD

FRANKLIN LAKES, N.J., July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that management will be presenting at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021, at 4:00 p.m.

BD to Present at UBS Genomics 2.0 and MedTech Innovations Summit

FRANKLIN LAKES, N.J., July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the company will begin remediation for the February 4, 2020 BD Alaris™ System 1  recall through a new version of software.

BD to Begin Remediation for BD Alaris™ System Software

Abbott Labs

Johnson & Johnson

You shouldn't invest your life savings into any one stock, but these three have some serious potential.

3 Dividend Stocks Safe Enough to Bet the Farm On

Cardinal Health

Medtronic

You can combine high-quality companies with mega-trends that are favorable for long-term growth with these dividend healthcare stocks. The post 3 Healthcare Stocks for Dividend Growth appeared first on InvestorPlace.

3 Healthcare Stocks for Dividend Growth

FRANKLIN LAKES, N.J., July 27, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

News for Becton, Dickinson and Co. Stock (BDX)